160 related articles for article (PubMed ID: 25171932)
1. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease.
Cohen-Aubart F; Emile JF; Maksud P; Galanaud D; Idbaih A; Chauvet D; Amar Y; Benameur N; Amoura Z; Haroche J
Neurology; 2014 Sep; 83(14):1294-6. PubMed ID: 25171932
[No Abstract] [Full Text] [Related]
2. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib.
Schirmer JH; Thorns C; Moosig F; Holle JU
Rheumatology (Oxford); 2015 Oct; 54(10):1932-4. PubMed ID: 26139656
[No Abstract] [Full Text] [Related]
3. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).
Cohen Aubart F; Emile JF; Carrat F; Charlotte F; Benameur N; Donadieu J; Maksud P; Idbaih A; Barete S; Hoang-Xuan K; Amoura Z; Haroche J
Blood; 2017 Sep; 130(11):1377-1380. PubMed ID: 28667012
[No Abstract] [Full Text] [Related]
4. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
[TBL] [Abstract][Full Text] [Related]
5. Orbital MRI Pre- and Post-Vemurafenib Therapy for Erdheim-Chester Disease.
Grumbine FL; Aderman C; Vagefi MR; Kersten RC
Ophthalmic Plast Reconstr Surg; 2015; 31(6):e169. PubMed ID: 25886699
[No Abstract] [Full Text] [Related]
6. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.
Tzoulis C; Schwarzlmüller T; Gjerde IO; Søfteland E; Neckelmann G; Biermann M; Haroche J; Straume O; Vintermyr OK
BMC Res Notes; 2015 Apr; 8():171. PubMed ID: 25926131
[TBL] [Abstract][Full Text] [Related]
7. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
8. Erdheim Chester disease with appendicular skeletal, renal and pleural involvement responding to Zelboraf (BRAF inhibitor) treatment: case report.
Borys D; Nystrom L; Song A; Lomasney LM
Skeletal Radiol; 2016 Oct; 45(10):1397-402. PubMed ID: 27423231
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
Cohen Aubart F; Emile JF; Maksud P; Galanaud D; Cluzel P; Benameur N; Aumaitre O; Amoura Z; Haroche J
Br J Haematol; 2018 Jan; 180(1):150-153. PubMed ID: 27711968
[No Abstract] [Full Text] [Related]
10. Saving orphans: BRAF targeting of histiocytosis.
Heaney ML
Blood; 2013 Feb; 121(9):1487-8. PubMed ID: 23449613
[TBL] [Abstract][Full Text] [Related]
11. A cytologic diagnosis of BRAF
Chasseur P; Kyriakopoulou M; Vokaer B; Beukinga I; Casado Arroyo R; Cogan E; Couturier B
Acta Clin Belg; 2017 Oct; 72(5):369-371. PubMed ID: 28222655
[TBL] [Abstract][Full Text] [Related]
12. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
[TBL] [Abstract][Full Text] [Related]
13. Erdheim-Chester disease.
Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
[TBL] [Abstract][Full Text] [Related]
14. Erdheim-Chester disease presenting with an intramedullary spinal cord lesion.
Tzoulis C; Gjerde IO; Søfteland E; Neckelmann G; Strøm E; Vintermyr OK; Sviland L; Biermann M
J Neurol; 2012 Oct; 259(10):2240-2. PubMed ID: 22638564
[No Abstract] [Full Text] [Related]
15. Erdheim-Chester disease: A challenging diagnosis for an effective therapy.
Todisco A; Cavaliere C; Vaglio A; Marano M; Bonometti A; Passoni E; Berti E; Cirillo M; Cirillo G
Clin Neurol Neurosurg; 2020 Jul; 194():105841. PubMed ID: 32330799
[No Abstract] [Full Text] [Related]
16. Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease.
Gupta A; Yeganeh A; Rootman D; Goldberg R
Ophthalmic Plast Reconstr Surg; 2017; 33(6):e138-e139. PubMed ID: 28099231
[TBL] [Abstract][Full Text] [Related]
17. [Erdheim-Chester disease].
Mazor RD; Shoenfeld Y
Harefuah; 2014 Jul; 153(7):389-91, 434, 433. PubMed ID: 25189027
[TBL] [Abstract][Full Text] [Related]
18. Orphan drug approval for Erdheim-Chester disease.
The Lancet Haematology
Lancet Haematol; 2017 Dec; 4(12):e562. PubMed ID: 29195598
[No Abstract] [Full Text] [Related]
19. Erdheim Chester disease: A rare obstructive case of acute renal failure.
Jean-Michel V; Coustans M; Wehbe B; Metes I; Siohan P
Presse Med; 2016 Nov; 45(11):1066-1069. PubMed ID: 27597297
[No Abstract] [Full Text] [Related]
20. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha.
Suzuki HI; Hosoya N; Miyagawa K; Ota S; Nakashima H; Makita N; Kurokawa M
Leuk Res; 2010 Jan; 34(1):e21-4. PubMed ID: 19679354
[No Abstract] [Full Text] [Related]
[Next] [New Search]
